Ribociclib and aromatase inhibitor for early breast cancer
Part of Cancer, Skin clinical trials.
This trial checks how well people stick to their prescribed ribociclib (Kisqali) plus aromatase inhibitor treatment for early-stage, hormone-receptor-positive, HER2-negative breast cancer, and monitors for side effects. It focuses on making sure patients are safe and supported while taking their medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- Your doctor has prescribed ribociclib (Kisqali) with an aromatase inhibitor for early-stage breast cancer
- You have not started your first cycle of ribociclib yet
- You have Slovenian health insurance and can speak and understand Slovenian
- You can participate by phone and are willing to give written consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.